RS50194B - Derivati 4-fenil-piridina i njihova primena kao antagonista nk-1 receptora - Google Patents
Derivati 4-fenil-piridina i njihova primena kao antagonista nk-1 receptoraInfo
- Publication number
- RS50194B RS50194B YUP-95/00A YUP9500A RS50194B RS 50194 B RS50194 B RS 50194B YU P9500 A YUP9500 A YU P9500A RS 50194 B RS50194 B RS 50194B
- Authority
- RS
- Serbia
- Prior art keywords
- alkyl
- group
- hydrogen
- thiomorpholin
- alkoxy
- Prior art date
Links
- 150000005362 4-phenylpyridines Chemical class 0.000 title 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- -1 C1-7-alkoxy Chemical class 0.000 abstract 5
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000001302 tertiary amino group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99103504 | 1999-02-24 | ||
EP99123689 | 1999-11-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
YU9500A YU9500A (sh) | 2002-11-15 |
RS50194B true RS50194B (sr) | 2009-05-06 |
Family
ID=26152908
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YUP-95/00A RS50194B (sr) | 1999-02-24 | 2000-02-22 | Derivati 4-fenil-piridina i njihova primena kao antagonista nk-1 receptora |
RSP-2008/0562A RS20080562A (en) | 1999-02-24 | 2000-02-22 | 4-phenyl-pyridine derivatives |
RS20080562A RS53869B1 (en) | 1999-02-24 | 2000-02-22 | 4-PHENYL-PYRIDINE DERIVATIVES |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RSP-2008/0562A RS20080562A (en) | 1999-02-24 | 2000-02-22 | 4-phenyl-pyridine derivatives |
RS20080562A RS53869B1 (en) | 1999-02-24 | 2000-02-22 | 4-PHENYL-PYRIDINE DERIVATIVES |
Country Status (54)
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3979099A (en) * | 1998-05-11 | 1999-11-29 | Philadelphia Health & Education Corporation | (mct-1), a human oncogene |
HUP0200124A3 (en) * | 1999-02-24 | 2004-03-01 | Hoffmann La Roche | Phenyl- and pyridinyl derivatives, process for their preparation and pharmaceutical compositions containing them |
US6291465B1 (en) * | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
EP1103545B1 (en) * | 1999-11-29 | 2003-11-05 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
JP3938651B2 (ja) * | 2000-04-13 | 2007-06-27 | セントラル硝子株式会社 | 光学活性α−メチル−ビス−3、5−(トリフルオロメチル)ベンジルアミンの製造方法 |
EP1303490B1 (en) | 2000-07-14 | 2008-07-09 | F. Hoffmann-La Roche Ag | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
DE60123661T2 (de) * | 2000-12-14 | 2007-08-16 | F. Hoffmann-La Roche Ag | Selbstemulgierende lipidmatrix (selm) |
US6531597B2 (en) * | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
ATE366248T1 (de) * | 2001-03-27 | 2007-07-15 | Eisai R&D Man Co Ltd | N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält |
ES2261657T3 (es) * | 2001-04-23 | 2006-11-16 | F. Hoffman-La Roche Ag | Derivados de hidrazida del acido pirrolidin-2-carboxilico para uso como inhibidores de metaloproteasa. |
EP1763350B1 (en) * | 2004-07-06 | 2011-12-21 | Xenon Pharmaceuticals Inc. | Nicotinamide derivatives and their use as therapeutic agents |
DE60143671D1 (de) * | 2001-06-07 | 2011-01-27 | Sang Christine | Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
MXPA04002220A (es) * | 2001-09-10 | 2004-06-07 | Hoffmann La Roche | Formulaciones tixotropicas oleosas. |
US7390813B1 (en) | 2001-12-21 | 2008-06-24 | Xenon Pharmaceuticals Inc. | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents |
BR0314126A (pt) | 2002-09-20 | 2005-06-28 | Pfizer Prod Inc | Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio |
AU2003298034B2 (en) | 2002-12-06 | 2011-04-21 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
US8729107B2 (en) * | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
DE602004007486T2 (de) * | 2003-01-31 | 2008-04-30 | F. Hoffmann-La Roche Ag | Neue kristallmodifikation von 2-(3,5-bis-trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-thiomorpholin-4-yl)-4(4-fluor-2-methyl-phenyl)-pyridin-3-yl-n-methyl-isobutyramid |
JP4490421B2 (ja) * | 2003-07-03 | 2010-06-23 | エフ.ホフマン−ラ ロシュ アーゲー | 統合失調症を処置するデュアルnk1/nk3アンタゴニスト |
TWI280239B (en) * | 2003-07-15 | 2007-05-01 | Hoffmann La Roche | Process for preparation of pyridine derivatives |
ATE527242T1 (de) | 2003-07-30 | 2011-10-15 | Xenon Pharmaceuticals Inc | Piperazin derivate und deren anwendung als therapeutische wirkstoffe |
KR100881240B1 (ko) * | 2004-07-06 | 2009-02-05 | 에프. 호프만-라 로슈 아게 | Nk-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법 |
ATE500224T1 (de) | 2004-07-06 | 2011-03-15 | Hoffmann La Roche | Herstellungsverfahren für carboxamid-pyridin- derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten |
US20060030556A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency |
WO2006013205A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
AR051094A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
EP1804799B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
TW200626154A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
TW200624427A (en) | 2004-09-20 | 2006-07-16 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
WO2006034338A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase |
MX2007003321A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
TW200626592A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
US7569725B2 (en) * | 2004-10-21 | 2009-08-04 | Britsol-Myers Squibb Company | Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US20060135636A1 (en) * | 2004-11-15 | 2006-06-22 | Honeywell International Inc. | Isocyanate-based polymer foams with nano-scale materials |
AU2006218179B2 (en) * | 2005-02-22 | 2010-12-23 | F. Hoffmann-La Roche Ag | NK1 antagonists |
AU2006216566A1 (en) * | 2005-02-24 | 2006-08-31 | Janssen Pharmaceutica N.V. | Novel pyridine derivatives as potassium ion channel openers |
BRPI0606187A2 (pt) | 2005-02-25 | 2009-06-09 | Hoffmann La Roche | comprimidos com capacidade de dispersão da substáncia do fármaco melhorada |
CA2602445C (en) * | 2005-03-23 | 2013-08-20 | F.Hoffmann-La Roche Ag | Metabolites for nk-i antagonists for emesis |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
NZ566208A (en) * | 2005-08-11 | 2010-09-30 | Vertex Pharma | 2-Thiazolamide derivatives as modulators of cystic fibrosis transmembrane conductance regulators |
WO2007028654A1 (en) | 2005-09-09 | 2007-03-15 | Smithkline Beecham Corporation | Pyridine derivatives and their use in the treatment of psychotic disorders |
RU2431473C2 (ru) * | 2005-09-23 | 2011-10-20 | Ф. Хоффманн-Ля Рош Аг | Новая лекарственная форма |
EP2774925B1 (en) | 2005-11-08 | 2016-12-28 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of ATP-binding cassette transporters |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7872022B2 (en) | 2006-04-03 | 2011-01-18 | Hoffmann-La Roche Inc. | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
SI2007756T1 (sl) | 2006-04-07 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Modulatorji prenašalcev z atp-vezavno kaseto |
USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
JP2011506330A (ja) | 2007-12-07 | 2011-03-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソル−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の固体状形態 |
KR101674404B1 (ko) * | 2007-12-07 | 2016-11-09 | 버텍스 파마슈티칼스 인코포레이티드 | 사이클로알킬카복시아미도-피리딘 벤조산의 제조 방법 |
EP2249650A4 (en) * | 2008-02-19 | 2012-01-11 | Glaxosmithkline Llc | ANILINOPYRIDINE AS A FAK HEMMER |
AU2009219363B2 (en) | 2008-02-28 | 2013-10-10 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as CFTR modulators |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
WO2011023733A1 (en) * | 2009-08-27 | 2011-03-03 | Glaxosmithkline Llc | Anhydrate forms of a pyridine derivative |
EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
MY159393A (en) | 2009-11-18 | 2016-12-30 | Helsinn Healthcare Sa | Compositions for treating centrally mediated nausea and vomiting |
TW201143768A (en) * | 2009-12-15 | 2011-12-16 | Lundbeck & Co As H | Pyridone derivatives as NK3 antagonists |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
AU2011237494C1 (en) | 2010-04-07 | 2016-05-26 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
EP3150198B1 (en) | 2010-04-07 | 2021-09-22 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
CA3108488A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
US20140256740A1 (en) * | 2011-07-29 | 2014-09-11 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
US20140155419A1 (en) * | 2011-07-29 | 2014-06-05 | Erkan Baloglu | Compounds and methods |
EP2759298B1 (en) | 2011-10-18 | 2018-01-17 | Helsinn Healthcare SA | Therapeutic combinations of netupitant and palonosetron |
IN2014KN00885A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) | 2011-11-08 | 2015-10-02 | Vertex Pharma | |
US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
US9012496B2 (en) | 2012-07-16 | 2015-04-21 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
RU2673084C2 (ru) * | 2013-11-08 | 2018-11-22 | Киссеи Фармасьютикал Ко., Лтд. | Производное карбоксиметилпиперидина |
SG10201803930QA (en) | 2013-11-12 | 2018-07-30 | Vertex Pharma | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
EP3925607B9 (en) | 2014-04-15 | 2025-07-16 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
WO2015171489A1 (en) * | 2014-05-05 | 2015-11-12 | Apicore Us Llc | Methods of making netupitant and intermediates thereof |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
TW201613888A (en) * | 2014-09-26 | 2016-04-16 | Helsinn Healthcare Sa | Crystalline forms of an NK-1 antagonist |
DK3221692T3 (da) | 2014-11-18 | 2021-08-23 | Vertex Pharma | Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi |
US10463655B2 (en) | 2015-03-04 | 2019-11-05 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
CN105061303A (zh) * | 2015-08-03 | 2015-11-18 | 成都欣捷高新技术开发有限公司 | 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法 |
CA2996717A1 (en) | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
ES2813596T3 (es) | 2015-12-07 | 2021-03-24 | Kissei Pharmaceutical | Antagonista del receptor NK1 |
US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
TW202246215A (zh) * | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
CN106892864A (zh) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | 一种奈妥皮坦游离碱的晶型a及其制备方法 |
WO2017112792A1 (en) * | 2015-12-22 | 2017-06-29 | Takeda Pharmaceutical Company Limited | Tripartite modulators of endosomal g protein-coupled receptors |
IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
EP3645120B1 (en) | 2017-06-30 | 2024-12-11 | Chase Therapeutics Corporation | Nk-1 antagonist compositions and methods for use in treating depression |
CN109384712B (zh) * | 2017-08-14 | 2021-05-07 | 北京宽厚医药科技有限公司 | 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用 |
EP3672964A4 (en) | 2017-08-21 | 2021-05-26 | Leiutis Pharmaceuticals Pvt. Ltd. | Novel triple combination formulations for antiemetic therapy |
JP7468964B2 (ja) * | 2018-09-28 | 2024-04-16 | バンダ・ファーマシューティカルズ・インコーポレイテッド | 動揺病におけるトラジピタントの使用 |
US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
AU2019414285B2 (en) * | 2018-12-24 | 2024-11-14 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Chemical compound manufacture, new salt form, and therapeutic uses thereof |
CN112174881B (zh) * | 2019-07-04 | 2022-06-21 | 上海森辉医药有限公司 | 一种奈妥匹坦的衍生物及其制备方法 |
AU2020337177B2 (en) * | 2019-08-23 | 2025-06-26 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Therapeutic methods and uses thereof |
WO2021198255A1 (en) | 2020-04-03 | 2021-10-07 | Nerre Therapeutics Limited | An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods) |
CA3177477A1 (en) | 2020-06-02 | 2021-12-09 | Nerre Therapeutics Limited | Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs |
US12097197B2 (en) | 2021-12-21 | 2024-09-24 | Slayback Pharma Llc | Stable liquid compositions of netupitant and palonosetron |
WO2024126408A1 (en) | 2022-12-12 | 2024-06-20 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
KR20250125376A (ko) | 2022-12-12 | 2025-08-21 | 알프레드 이. 티펜바흐어 게엠베하 운트 & 코. 카게 | 네투피탄트 및 팔로노세트론을 포함하는 고정 용량 복합제 |
EP4385500A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Fixed dose combination comprising netupitant and palonosetron |
EP4385497A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1557420A (en) | 1977-03-10 | 1979-12-12 | Soc D Etudes Prod Chimique | Preparation of isobutyramide derivatives |
KR810001320B1 (ko) | 1977-03-17 | 1981-10-14 | 삐에르 위브 | 신규한 이소부티라미드류의 제조방법 |
KR810001697B1 (ko) | 1978-02-06 | 1981-10-27 | 삐에르 위브 | 이소부티라미드 유도체의 신규한 제조방법 |
EP0089765A3 (en) | 1982-03-17 | 1984-05-23 | Smith Kline & French Laboratories Limited | Pyridine derivatives |
US4745123A (en) * | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
GB8607312D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
GB8607313D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
CA1339423C (en) | 1988-09-14 | 1997-09-02 | Yuji Ono | Pyridine compounds and pharmaceutical use thereof |
US4994456A (en) | 1989-03-01 | 1991-02-19 | Nisshin Flour Milling Co., Ltd. | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same |
US4973597A (en) | 1989-06-30 | 1990-11-27 | Eli Lilly And Company | Anticonvulsant agents |
HU207047B (en) | 1989-11-07 | 1993-03-01 | Richter Gedeon Vegyeszet | Process for producing new pyridine derivatives and pharmaceutical copositions comprising same |
US5364943A (en) | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
GB9021056D0 (en) | 1990-09-27 | 1990-11-07 | Pfizer Ltd | Antiarrhythmic agents |
GB9214120D0 (en) | 1991-07-25 | 1992-08-12 | Ici Plc | Therapeutic amides |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
AU4718093A (en) | 1992-07-31 | 1994-03-03 | Merck Sharp & Dohme Limited | Substituted amines as tachykinin receptor antagonists |
US5387595A (en) | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
GB9305672D0 (en) | 1993-03-19 | 1993-05-05 | Wyeth John & Brother Ltd | Amide derivatives |
NZ264063A (en) | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
WO1995018124A1 (en) | 1993-12-29 | 1995-07-06 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
DK0764163T3 (da) | 1994-06-06 | 2002-02-04 | Warner Lambert Co | Tachykinin (NK1) receptor-antagonister |
US6294537B1 (en) | 1995-03-17 | 2001-09-25 | Sanofi-Synthelabo | Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools |
DE69628484T2 (de) * | 1995-03-24 | 2004-05-19 | Takeda Chemical Industries, Ltd. | Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten |
AR004735A1 (es) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
UA49006C2 (uk) | 1996-03-29 | 2002-09-16 | Файзер Інк. | Похідні 6-фенілпіридил-2-аміну, фармацевтична композиція, спосіб інгібування синтази оксиду нітрогену у ссавців та спосіб лікування |
AU4885097A (en) | 1996-11-08 | 1998-06-03 | Sankyo Company Limited | Arylureas or arylmethylcarbamoyl derivatives |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
HUP0200124A3 (en) * | 1999-02-24 | 2004-03-01 | Hoffmann La Roche | Phenyl- and pyridinyl derivatives, process for their preparation and pharmaceutical compositions containing them |
EP1103545B1 (en) * | 1999-11-29 | 2003-11-05 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
-
2000
- 2000-02-15 PT PT03026298T patent/PT1394150E/pt unknown
- 2000-02-15 SE SE00102260T patent/SE1035115T5/xx unknown
- 2000-02-15 AT AT03026298T patent/ATE496032T1/de active
- 2000-02-15 EP EP03026298A patent/EP1394150B1/en not_active Expired - Lifetime
- 2000-02-15 SI SI200030506T patent/SI1035115T1/xx unknown
- 2000-02-15 DK DK00102260T patent/DK1035115T3/da active
- 2000-02-15 PT PT00102260T patent/PT1035115E/pt unknown
- 2000-02-15 DE DE60014216T patent/DE60014216T2/de not_active Expired - Lifetime
- 2000-02-15 ES ES00102260T patent/ES2226622T3/es not_active Expired - Lifetime
- 2000-02-15 DE DE60045564T patent/DE60045564D1/de not_active Expired - Lifetime
- 2000-02-15 ES ES03026298T patent/ES2359235T3/es not_active Expired - Lifetime
- 2000-02-15 AT AT00102260T patent/ATE277905T1/de active
- 2000-02-15 DK DK03026298.4T patent/DK1394150T3/da active
- 2000-02-15 EP EP00102260A patent/EP1035115B1/en not_active Expired - Lifetime
- 2000-02-18 PE PE2000000125A patent/PE20001467A1/es not_active IP Right Cessation
- 2000-02-18 GB GB0003908A patent/GB2347422A/en not_active Withdrawn
- 2000-02-18 NZ NZ502948A patent/NZ502948A/en not_active IP Right Cessation
- 2000-02-21 IL IL134654A patent/IL134654A/en active Protection Beyond IP Right Term
- 2000-02-21 CZ CZ20000609A patent/CZ300596B6/cs not_active IP Right Cessation
- 2000-02-21 GE GEAP20005227A patent/GEP20022676B/en unknown
- 2000-02-21 HU HU0000748A patent/HU227629B1/hu unknown
- 2000-02-22 IS IS5381A patent/IS2116B/is unknown
- 2000-02-22 SK SK235-2000A patent/SK287911B6/sk not_active IP Right Cessation
- 2000-02-22 AR ARP000100737A patent/AR029614A1/es active IP Right Grant
- 2000-02-22 JO JO200014A patent/JO2294B1/en active
- 2000-02-22 EG EG20000206A patent/EG23817A/xx active
- 2000-02-22 MY MYPI20000648A patent/MY123648A/en unknown
- 2000-02-22 DE DE10008042A patent/DE10008042A1/de not_active Withdrawn
- 2000-02-22 SK SK5052-2008A patent/SK287912B6/sk not_active IP Right Cessation
- 2000-02-22 RS YUP-95/00A patent/RS50194B/sr unknown
- 2000-02-22 ME MEP-2009-57A patent/ME00593B/me unknown
- 2000-02-22 RS RSP-2008/0562A patent/RS20080562A/sr unknown
- 2000-02-22 TN TNTNSN00032A patent/TNSN00032A1/fr unknown
- 2000-02-22 GT GT200000017A patent/GT200000017A/es unknown
- 2000-02-22 MY MYPI20044751A patent/MY147451A/en unknown
- 2000-02-22 RS RS20080562A patent/RS53869B1/en unknown
- 2000-02-22 PA PA20008491101A patent/PA8491101A1/es unknown
- 2000-02-22 US US09/507,456 patent/US6297375B1/en not_active Expired - Lifetime
- 2000-02-22 FR FR0002170A patent/FR2790473B1/fr not_active Expired - Fee Related
- 2000-02-22 UA UA2000021039A patent/UA71547C2/uk unknown
- 2000-02-23 NO NO20000885A patent/NO315554B1/no not_active IP Right Cessation
- 2000-02-23 HR HR20000097A patent/HRP20000097B1/xx not_active IP Right Cessation
- 2000-02-23 SG SG200001033A patent/SG91856A1/en unknown
- 2000-02-23 ES ES200000418A patent/ES2171109B2/es not_active Expired - Fee Related
- 2000-02-23 CA CA2299139A patent/CA2299139C/en not_active Expired - Lifetime
- 2000-02-23 SV SV2000000024A patent/SV2002000024A/es active IP Right Grant
- 2000-02-23 ZA ZA200000894A patent/ZA200000894B/xx unknown
- 2000-02-23 MA MA25913A patent/MA26722A1/fr unknown
- 2000-02-23 CN CNB001024019A patent/CN1142144C/zh not_active Expired - Lifetime
- 2000-02-23 BR BRPI0000908A patent/BRPI0000908B8/pt not_active IP Right Cessation
- 2000-02-23 KR KR10-2000-0008674A patent/KR100384904B1/ko not_active Expired - Lifetime
- 2000-02-23 IT IT2000MI000328A patent/IT1320763B1/it active
- 2000-02-23 EA EA200000155A patent/EA003673B1/ru active Protection Beyond IP Right Term
- 2000-02-24 BG BG104187A patent/BG64554B1/bg unknown
- 2000-02-24 TR TR2000/00520A patent/TR200000520A2/xx unknown
- 2000-02-24 JP JP2000047003A patent/JP3399900B2/ja not_active Expired - Lifetime
- 2000-02-24 AU AU19468/00A patent/AU767048B2/en not_active Expired
- 2000-02-24 PL PL338598A patent/PL217311B1/pl unknown
- 2000-02-24 OA OA1200000052A patent/OA11680A/fr unknown
- 2000-02-25 TW TW089103387A patent/TWI288746B/zh not_active IP Right Cessation
-
2001
- 2001-07-10 US US09/901,982 patent/US6479483B2/en not_active Expired - Lifetime
-
2007
- 2007-09-24 AR ARP070104196A patent/AR062949A2/es active IP Right Grant
-
2008
- 2008-06-27 HR HRP20080306AA patent/HRP20080306B1/hr not_active IP Right Cessation
-
2009
- 2009-12-10 UY UY0001032314A patent/UY32314A/es not_active Application Discontinuation
-
2011
- 2011-02-10 CY CY20111100162T patent/CY1111317T1/el unknown
-
2015
- 2015-06-17 LU LU92745C patent/LU92745I2/xx unknown
- 2015-07-08 FR FR15C0049C patent/FR15C0049I2/fr active Active
- 2015-08-28 NL NL300758C patent/NL300758I2/nl unknown
- 2015-10-21 LT LTPA2015036C patent/LTC1035115I2/lt unknown
- 2015-10-29 CY CY2015042C patent/CY2015042I1/el unknown
- 2015-10-29 CY CY2015041C patent/CY2015041I2/el unknown
- 2015-10-29 BE BE2015C057C patent/BE2015C057I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS50194B (sr) | Derivati 4-fenil-piridina i njihova primena kao antagonista nk-1 receptora | |
NZ513370A (en) | 3-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | |
RS52326B (en) | Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors | |
DE60204674D1 (de) | Retinoid x rezeptormodulatoren | |
TR200401546T4 (tr) | Piperazin türevleri, hazırlanmaları ve merkezi sinir sistemi (CNS) bozukluklarının tedavisinde kullanımları | |
LU91676I2 (fr) | "Valsartan, amlodipine et hydrochlorothiazide et leur sel pharmaceutiquement acceptable - EXFORGIE HCT" | |
CA2364665A1 (en) | Phenyl- and pyridinyl derivatives | |
DE502005001916D1 (de) | Substituierte oxindol-derivate und diese enthaltende arzneimittel | |
BR9507910A (pt) | Derivados da piperazina como antagonistas de 5-ht1a | |
WO2001032644A3 (en) | Excitatory amino acid derivatives | |
FI945581A0 (fi) | Substituoidut (aryylialkoksibentsyyli) aminopropaaniamidijohdannaiset, niiden valmistus ja käyttö antiepileptisinä, neuroprotektiivisina ja antidepressiivisinä aineina | |
AU2003207432A1 (en) | Urea linker derivatives for use as ppar modulators | |
ATE200486T1 (de) | Pyrimidin derivate | |
NZ513824A (en) | Biphenyl derivatives as antagonists of the neurokinine-1 receptor | |
GB9924836D0 (en) | Novel antidiuretic agents | |
PL306538A1 (en) | Substituted (aryloalkylaminobenzyl) amino propanamide derivatives, method of obtaining them and their application as antiepileptic, nervous system protecting and antidepressive agents | |
MXPA03010437A (es) | Derivados de 4-(fenil-piperidin-4-iliden-metil)-benzamida y su uso para tratar dolor, ansiedad o transtornos gastrointestinales. | |
DE69505362D1 (de) | Biphenyl-derivate als 5ht1d antagonisten | |
CA2423357A1 (en) | Fused heterocyclic derivatives as phosphodiesterase inhibitors | |
IL61769A (en) | 2-(n-(halosubstitutedphenyl)-n-(thienyl-2-methyl)-amino)-2-imidazolines,their preparation and pharmaceutical compositions containing them |